title: Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
abstract: BACKGROUND
  We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis.
  
  
  METHODS
  Patients who had received isoniazid for treatment of latent tuberculosis were included in the study. Hepatotoxicity was classified according to the World Health Organization Toxicity Classification Standards.
  
  
  RESULTS
  Among 1038 patients, overall hepatotoxicity was observed in 22 patients (2.2%), while 5 patients (0.48%) had moderate-severe hepatotoxicity; while other 17 patients had grade I-II hepatotoxicity (1.63%). Age and gender did not appear to be risk factors for hepatotoxicity. The median time for therapy rechallenge in patients with grade III-IV hepatotoxicity was 21 days (ranging from 14 to 25 days).
  
  
  CONCLUSIONS
  Isoniazid hepatotoxicity is lower and generally reversible after cessation of INH in children. The grade of hepatotoxicity affects the duration for recovery of hepatotoxicity and restarting of INH therapy.
authors.affiliation: Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: İlker
authors.initials: İ
authors.lastname: Devrim
authors.affiliation: Department of, Pediatrics, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: Fatma
authors.initials: F
authors.lastname: Devrim
authors.affiliation: Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey - nuribayram@gmail.com.
authors.forename: Nuri
authors.initials: N
authors.lastname: Bayram
authors.affiliation: Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Aktürk
authors.affiliation: Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: Ahu
authors.initials: A
authors.lastname: Aksay
authors.affiliation: Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: Demet
authors.initials: D
authors.lastname: Can
authors.affiliation: Department of Pediatric Infectious Diseases, Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
authors.forename: Hurşit
authors.initials: H
authors.lastname: Apa
mesh_terms: D000293:Adolescent; D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007538:Isoniazid / Q000009:adverse effects*; D055985:Latent Tuberculosis / Q000188:drug therapy*; D008297:Male
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid